Aurinia Pharmaceuticals Inc (AUPH)
5.155
-0.04
(-0.87%)
USD |
NASDAQ |
May 02, 16:00
5.155
0.00 (0.00%)
After-Hours: 18:08
Aurinia Pharmaceuticals Enterprise Value: 393.21M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 01, 2024 | 393.21M |
April 30, 2024 | 377.48M |
April 29, 2024 | 366.04M |
April 26, 2024 | 351.74M |
April 25, 2024 | 349.35M |
April 24, 2024 | 372.35M |
April 23, 2024 | 380.97M |
April 22, 2024 | 375.22M |
April 19, 2024 | 371.15M |
April 18, 2024 | 345.12M |
April 17, 2024 | 359.58M |
April 16, 2024 | 372.60M |
April 15, 2024 | 378.38M |
April 12, 2024 | 387.06M |
April 11, 2024 | 384.17M |
April 10, 2024 | 371.15M |
April 09, 2024 | 388.51M |
April 08, 2024 | 369.71M |
April 05, 2024 | 379.83M |
April 04, 2024 | 385.62M |
April 03, 2024 | 398.63M |
April 02, 2024 | 384.17M |
April 01, 2024 | 430.45M |
March 28, 2024 | 374.05M |
March 27, 2024 | 372.60M |
Date | Value |
---|---|
March 26, 2024 | 362.48M |
March 25, 2024 | 371.15M |
March 22, 2024 | 368.26M |
March 21, 2024 | 374.05M |
March 20, 2024 | 392.85M |
March 19, 2024 | 398.63M |
March 18, 2024 | 385.62M |
March 15, 2024 | 397.18M |
March 14, 2024 | 385.62M |
March 13, 2024 | 408.75M |
March 12, 2024 | 401.52M |
March 11, 2024 | 426.11M |
March 08, 2024 | 434.79M |
March 07, 2024 | 437.68M |
March 06, 2024 | 447.80M |
March 05, 2024 | 459.37M |
March 04, 2024 | 482.51M |
March 01, 2024 | 485.40M |
February 29, 2024 | 476.72M |
February 28, 2024 | 494.08M |
February 27, 2024 | 520.11M |
February 26, 2024 | 517.22M |
February 23, 2024 | 509.99M |
February 22, 2024 | 517.22M |
February 21, 2024 | 479.62M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
207.43M
Minimum
Dec 27 2022
4.000B
Maximum
Oct 29 2021
1.183B
Average
1.176B
Median
Mar 30 2023
Enterprise Value Benchmarks
Lexaria Bioscience Corp | 39.61M |
Acasti Pharma Inc | 1.675M |
Edesa Biotech Inc | 9.854M |
Xenon Pharmaceuticals Inc | 2.568B |
ESSA Pharma Inc | 150.96M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -26.88M |
Revenue (Quarterly) | 45.10M |
Total Expenses (Quarterly) | 74.77M |
EPS Diluted (Quarterly) | -0.18 |
Gross Profit Margin (Quarterly) | 88.04% |
Profit Margin (Quarterly) | -59.60% |
Earnings Yield | -10.28% |
Normalized Earnings Yield | -10.28 |